Breast cancer radiation cut to just 9 days in new trial
NCT ID NCT03345420
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested a 9-day course of whole breast radiation (hypofractionated radiotherapy) in 102 patients with early-stage breast cancer (stage 0-IIB). The goal was to see if a shorter treatment time could maintain effectiveness while reducing side effects. Researchers evaluated cosmetic outcomes and quality of life up to 24 months after radiation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- hypofractionated radiation therapy
- What this could lead to
- If successful, this shorter radiation course could become a standard option for early-stage breast cancer, reducing treatment burden and side effects.
- What could go wrong
- This is a phase II trial with only 102 participants, so results are preliminary. The shorter course may not be as effective or safe as standard longer regimens in all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCTAL BREAST CARCINOMA IN SITU are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fasting during chemo: a new way to boost treatment?
- Can radiation replace surgery for cancer spread to lymph nodes?
- Could a common cholesterol drug boost breast cancer treatment?
- Gene test could guide breast cancer treatment to boost survival
- One-Week radiation for breast cancer: MRI precision may cut side effects
- Triple threat: new combo shows promise against tough breast cancer